This is but a fact that obesity drugs are only going to get more accessible for Indians post March 2026. But whether they make us healthier depends on how we use them. If they become another ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

In the past year or couple of years, you’ve likely heard a lot about Ozempic, most likely in the context of weight loss. Not ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Multiple lawsuits have been filed against the makers of the popular weight-loss drug. Litigants cite blindness and other side ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...